Media

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic RCC Database Consortium - Shaan Dudani

Details
Shaan Dudani joins Monty Pal and Jaime Landman, sharing an overview of the First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium which was published this past August in European urology. Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patient...

PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain

Details
Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...

Continuing the Momentum with Patient Advocacy - Elisabeth Heath

Details
Elisabeth Heath from the Karmanos Cancer Institute joins Alicia Morgans in a passionate conversation on the importance of patient advocacy, education, and the impact advocacy has on a cancer patients' journey. What resources are out there? How do we really help patients do the best that they can? How do you find advocacy organizations in your community? and, How do you get involved? Drs. Heath and...

Karmanos Cancer Institute's 9th Annual Cancer Symposium - Elisabeth Heath

Details
Elisabeth Heath from the Karmanos Cancer Institute shares details on the upcoming Karmanos Cancer Institute's 9th Annual Cancer Symposium taking place this October. In response to such high demand and attendance, this is the first year the Symposium has been expanded to include all cancer types in addition to prostate cancer. This year's agenda focuses on Progress in Cancer Care, Advocacy and Surv...

Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke

Details
Using various volume and risk criteria used worldwide for the treatment related to docetaxel and abiraterone in metastatic hormone-sensitive prostate cancer, Noel Clarke and colleagues have gathered and correlated large volumes of imaging data on treatment and outcomes from within the UK within the STAMPEDE trial. In his discussion with Charles Ryan, Noel Clarke shares details of the sub-analysis...

Radium 223 Dichloride Use in Patients with Castrate Resistant Prostate Cancer - Hossein Jadvar

Details
Hossein Jadvar joins Phillip Koo for the last in its series of video presentations in the Society of Nuclear Medicine SNMMI video lecture series. Dr. Jadvar presents on the topic of Radium 223 dichloride use in patients with castrate-resistant prostate cancer. (Length of Interview: 34 min) Biographies: Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer...

Imaging Modalities to Treat Node-Positive Disease - Interview with Declan Murphy

Details
Declan Murphy sits down with Alicia Morgans during the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to discuss men who have node positive but nonmetastatic prostate cancer and how we think about approaching treatment and integrating new imaging modalities into that entire therapeutic paradigm. Two aspects of managing node positive men in regards to surgery were talked about including...

Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke

Details
Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...

How to Treat Men with pN1 Prostate Cancer - Presentation - Alberto Bossi

Details
Alberto Bossi presented on the recommended treatment for men with pathological node-positive prostate cancer. These patients are becoming more common as surgery is being performed on a higher proportion of high-risk patients with positive nodes. Highlighting unanswered questions regarding the treatment of these patients following surgery, Dr. Alberto Bossi mentions several studies that have assess...

Advantages of PSMA PET in APC Imaging Presentation - Stefano Fanti

Details
At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Stefano Fanti presented the advantages of PSMA PET-CT in advanced prostate cancer imaging. He highlighted the role of PSMA PET-CT in staging, biochemical recurrence, and therapy planning. Biography: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Director of Nuclear Medic...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe